Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 903, Issue , 2012, Pages 150-156

  Kralj, Eva ^a   Trontelj, Jurij ^a   Pajič, Tadej ^b   Kristl, Albin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Dasatinib; DBS; Imatinib; LC MS MS; Nilotinib

Indexed keywords

DASATINIB; DBS; IMATINIB; LC-MS/MS; NILOTINIB;

ACETONITRILE; AMINO ACIDS; DRUG THERAPY; FORMIC ACID; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHANOL; PATIENT MONITORING;

BLOOD;

ACETONITRILE; DASATINIB; FORMIC ACID; IMATINIB; METHANOL; NILOTINIB;

ACCURACY; ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DOSE RESPONSE; DRIED BLOOD SPOT TESTING; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; HEMATOCRIT; HUMAN; ISOTOPE LABELING; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REFRIGERATOR; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; SPIKE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRIED BLOOD SPOT TESTING; DRUG STABILITY; HUMANS; LINEAR MODELS; PIPERAZINES; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; THIAZOLES;

EID: 84864925912     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.07.011     Document Type: Article

References (36)

1. Capdeville R., Buchdunger E., Zimmermann J., Matter A. Nat. Rev. Drug Discov. 2002, 1:493.
2. Moen M.D., McKeage K., Plosker G.L., Siddiqui M.A. Drugs 2007, 67:299.
3. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., Druker B.J. N. Engl. J. Med. 2003, 348:1001.
4. Milojkovic D., Apperley J. Clin. Cancer Res. 2009, 15:7519.
5. Shah N.P., Sawyers C.L. Oncogene 2003, 22:7389.
6. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., Lassalle R., Marit G., Reiffers J., Begaud B., Moore N., Molimard M., Mahon F.X. Blood 2007, 109:3496.
7. Skorski T. Curr. Hematol. Malig. Rep. 2007, 2:69.
8. Kantarjian H.M., Talpaz M., O'Brien S., Giles F., Garcia-Manero G., Faderl S., Thomas D., Shan J., Rios M.B., Cortes J. Blood 2003, 101:473.
9. Widmer N., Decosterd L.A., Csajka C., Leyvraz S., Duchosal M.A., Rosselet A., Rochat B., Eap C.B., Henry H., Biollaz J., Buclin T. Br. J. Clin. Pharmacol. 2006, 62:97.
10. Sakai M., Miyazaki Y., Matsuo E. Int. J. Hematol. 2009, 89:319.
11. Ibrahim A.R., Eliasson L., Apperley J.F., Milojkovic D., Bua M., Szydlo R., Mahon F.-X., Kozlowski K., Paliompeis C., Foroni L., Khorashad J.S., Bazeos A., Molimard M., Reid A., Rezvani K., Gerrard G., Goldman J., Marin D. Blood 2011, 117:3733.
12. EUTOS for CML, http://www.eutos.org/content/path_to_cure/documents/research/e123/infoboxContent228/EUTOS_BLT_backgrndr_160708.pdf.
13. Saglio G., Kim D.W., Issaragrisil S., le Coutre P., Etienne G., Lobo C., Pasquini R., Clark R.E., Hochhaus A., Hughes T.P., Gallagher N., Hoenekopp A., Dong M., Haque A., Larson R.A., Kantarjian H.M., ENESTnd Investigators N. Engl. J. Med. 2010, 362:2251.
14. Kantarjian H.M., Hochhaus A., Saglio G., De Souza C., Flinn I.W., Stenke L., Goh Y.T., Rosti G., Nakamae H., Gallagher N.J., Hoenekopp A., Blakesley R.E., Larson R.A., Hughes T.P. Lancet Oncol. 2011, 12:841.
15. Steinberg M. Clin. Ther. 2007, 29:2289.
16. DeRemer D.L., Ustun C., Natarajan K. Clin. Ther. 2008, 30:1956.
17. Guoqing W., Shamudheen R., Delong L. J. Hematol. Oncol. 2010, 3:47.
18. Christopher L.J., Cui D., Wu C., Luo R., Manning J.A., Bonacorsi S.J., Lago M., Allentoff A., Lee F.Y.F., McCann B., Galbraith S., Reitberg D.P., He K., Barros A., Blackwood-Chirchir A., Humphreys W.G., Iyer R.A. Drug Metab. Dispos. 2008, 36:1341.
19. Haouala A., Widmer N., Duchosal M.A., Montemurro M., Buclin T., Decosterd L.A. Blood 2011, 117:e75.
20. Haoualaa, Zanolaria B., Rochatb B., Montemurrod M., Zamand K., Duchosale M.A., Risc H.B., Leyvrazd S., Widmera N., Decosterd L.A. J. Chromatogr. B 2009, 877.
21. Bouchet S., Chauzit E., Ducint D., Castaing N., Canal-Raffin M., Moore N., Titier K., Molimard M. Clin. Chim. Acta 2011, 412:1060.
22. De Francia S., D'Avolio A., De Martino F., Pirro E., Baietto L., Siccardi M., Simiele M., Racca S., Saglio G., Di Carlo F., Di Perri G. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2009, 877:1721.
23. Chiu M.L., Lawi W., Snyder S.T., Wong P.K., Liao J.C., Gau V. JALA 2010, 15:233.
24. Rao R.N., Maurya P.K., Ramesh M., Srinivas R., Agwane S.B. Biomed. Chromatogr. 2010, 24:1356.
25. Li W., Tse F.L.S. Biomed. Chromatogr. 2010, 24:49.
26. Spooner N., Ramakrishnan Y., Barfield M., Dewitt O., Miller S. Bioanalysis 2010, 2:1343.
27. U.S.FDA Guidance for Industry, Bioanalytical Method Validation 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM07010.pdf.
28. Houghton R. Quotient Bioresearch Spring Seminar 2011, (accessed May 2012). http://landing.quotientbioresearch.com/blog/bid/55970/DBS-Method-Validation.
29. Matuszewski B.K. J. Chromatogr. B 2006, 830:293.
30. Chowdhury M.M., Kim D.H., Ahn J.K. Bull. Korean Chem. Soc. 2011, 32:11.
31. Kretz O., Weiss H.M., Schumacher M.M., Gross G. Br. J. Clin. Pharmacol. 2004, 58:212.
32. TASIGNA, INN nilotinib, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000798/WC500034394.pdf.
33. Kamath A.V., Wang J., Lee F.Y., Marathe P.H. Cancer Chemother. Pharmacol. 2008, 61:365.
34. Murphy J.E., Peltier T., Anderson D., Ward E.S. Ther. Drug Monit. 1990, 12:217.
35. Mohammed B.S., Cameron G.A., Cameron L., Hawksworth G.H., Helms P.J., McLay J.S. Br. J. Clin. Pharmacol. 2010, 70:52.
36. Rowland M., Emmons G.T. AAPSJ 2010, 12:290.